Pegylated interferon beta-1a (Plegridy) was separated from the MTA of beta interferons and glatiramer acetate for treating multiple sclerosis because a separate single technology appraisal for this technology is considered more appropriate so that the benefits of the technology can be fully considered. The Department of Health’s Risk Sharing Scheme formed the basis of the MTA but did not collect data on Plegridy, and there has been no agreed way to combine data from the Risk Sharing Scheme with those from the clinical trials for Plegridy. Carrying out a separate single technology appraisal on Plegridy will be consistent with other newer disease modifying treatments appraised by NICE. NICE will initiate this appraisal as a matter of priority. We will provide an update on the future timelines as soon as we can.